^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    maplirpacept (TTI-622)

    i
    Other names: TTI-622, PF-07901801, TTI622, TTI 622, SIRPa-IgG4-Fc
    Associations

    News

    Trials
    Company:
    Pfizer
    Drug class:
    CD47 inhibitor
    Related drugs:
    Associations

    News

    Trials
    9d
    MagnetisMM-20: A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=90, Recruiting, Pfizer | Trial primary completion date: Aug 2025 --> Feb 2026
    Trial primary completion date • Combination therapy
    |
    carfilzomib • Elrexfio (elranatamab-bcmm) • maplirpacept (TTI-622)
    1m
    Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With Platinum-Resistant Ovarian Cancer (clinicaltrials.gov)
    P1/2, N=10, Terminated, Pfizer | Active, not recruiting --> Terminated; A business decision was made by Pfizer to terminate and remove the Phase 2 expansion of this study for administrative reasons. The reason for study termination is not due to any safety concerns or requests from regulatory authorities.
    Trial termination • Combination therapy
    |
    pegylated liposomal doxorubicin • maplirpacept (TTI-622)
    1m
    A Study to Learn About the Effects of Two Study Medicines (Maplirpacept [PF-07901801] And Glofitamab) When Given Together In People With Relapsed Or Refractory Diffuse Large B Cell Lymphoma. (clinicaltrials.gov)
    P1/2, N=70, Recruiting, Pfizer | Phase classification: P2 --> P1/2
    Phase classification • Combination therapy
    |
    Gazyva (obinutuzumab) • Columvi (glofitamab-gxbm) • maplirpacept (TTI-622)
    1m
    MagnetisMM-20: A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=90, Recruiting, Pfizer | N=14 --> 90
    Enrollment change • Combination therapy
    |
    carfilzomib • Elrexfio (elranatamab-bcmm) • maplirpacept (TTI-622)
    3ms
    A Study to Learn About the Study Medicine (Called Maplirpacept (PF-07901801)) in Japanese With Hematologic Malignancies (clinicaltrials.gov)
    P1, N=7, Active, not recruiting, Pfizer | Recruiting --> Active, not recruiting | N=13 --> 7
    Enrollment closed • Enrollment change
    |
    maplirpacept (TTI-622)
    3ms
    A Study of TTI-622 in Combination With Daratumumab Hyaluronidase-fihj in People With Multiple Myeloma (clinicaltrials.gov)
    P1, N=7, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Recruiting --> Active, not recruiting | N=32 --> 7
    Enrollment closed • Enrollment change • Combination therapy
    |
    Darzalex Faspro (daratumumab/hyaluronidase) • maplirpacept (TTI-622)
    4ms
    A Study to Learn About the Study Medicine (Maplirpacept) in People With Advanced Non-Hodgkin Lymphoma or Multiple Myeloma in China (clinicaltrials.gov)
    P1, N=9, Recruiting, Pfizer | Trial completion date: Nov 2024 --> May 2025 | Trial primary completion date: Aug 2024 --> Feb 2025
    Trial completion date • Trial primary completion date • Metastases
    |
    maplirpacept (TTI-622)
    5ms
    TTI-622-01: A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma (clinicaltrials.gov)
    P1, N=177, Active, not recruiting, Pfizer | Phase classification: P1a/1b --> P1 | Trial completion date: Mar 2025 --> Sep 2024 | Trial primary completion date: Mar 2024 --> Sep 2024
    Phase classification • Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation • TP53 wild-type
    |
    Venclexta (venetoclax) • Rituxan (rituximab) • azacitidine • carfilzomib • Sarclisa (isatuximab-irfc) • dexamethasone injection • maplirpacept (TTI-622)
    5ms
    A Study to Learn About the Effects of Two Study Medicines (Maplirpacept [PF-07901801] And Glofitamab) When Given Together In People With Relapsed Or Refractory Diffuse Large B Cell Lymphoma. (clinicaltrials.gov)
    P2, N=70, Recruiting, Pfizer | Phase classification: P1b/2 --> P2
    Phase classification • Combination therapy
    |
    Gazyva (obinutuzumab) • Columvi (glofitamab-gxbm) • maplirpacept (TTI-622)
    5ms
    Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma (clinicaltrials.gov)
    P2, N=70, Recruiting, Pfizer | Phase classification: P1b/2 --> P2
    Phase classification
    |
    lenalidomide • Monjuvi (tafasitamab-cxix) • maplirpacept (TTI-622)
    5ms
    A Multicenter, Open-Label, Phase 1b/2 Study to Evaluate the Effects of Maplirpacept in Combination with Tafasitamab and Lenalidomide in People with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (ASH 2023)
    Participants must provide a baseline tumor tissue sample (fresh or archival), for biomarker analysis. Exclusion criteria include previous treatment with anti-CD47, anti-CD19 (other than CAR-T) or immunomodulatory agents, prior allogeneic stem cell transplantation or autologous stem cell transplantation within 12 weeks prior to enrolment, and participants with active, uncontrolled viral, bacterial or fungal infections.
    Clinical • P1/2 data • Combination therapy • IO biomarker
    |
    lenalidomide • Monjuvi (tafasitamab-cxix) • maplirpacept (TTI-622)
    5ms
    A Multicenter, Open-Label, Phase 1b/2 Study to Evaluate the Effects of Maplirpacept in Combination with Glofitamab in People with Relapsed or Refractory Diffuse Large B Cell Lymphoma (ASH 2023)
    Background Maplirpacept (PF-07901801) is an anti-CD47 fusion protein constructed to enhance phagocytosis and antitumor activity via inhibition of CD47-mediated signaling. All patients should have adequate bone marrow, hepatic, and renal function (eGFR ≥45 mL/min) and ECOG performance status ≤2. Exclusion criteria include prior treatment with an anti-CD47 agent, prior anti-CD20xCD3 containing regimen, refractoriness to an obinutuzumab monotherapy containing regimen, prior allogeneic stem cell transplantation or autologous stem cell transplantation within 12 weeks prior to enrolment, high grade B-cell lymphoma with BCL2 and Myc rearrangement, active bacterial, viral, fungal, mycobacterial, parasitic, or other infection.
    Clinical • P1/2 data • Combination therapy
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    MYC rearrangement • BCL2 rearrangement
    |
    Gazyva (obinutuzumab) • Columvi (glofitamab-gxbm) • maplirpacept (TTI-622)
    6ms
    MagnetisMM-20: A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=14, Recruiting, Pfizer | Phase classification: P1b --> P1
    Phase classification • Combination therapy
    |
    carfilzomib • Elrexfio (elranatamab-bcmm) • maplirpacept (TTI-622)
    6ms
    Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With Platinum-Resistant Ovarian Cancer (clinicaltrials.gov)
    P1/2, N=10, Active, not recruiting, Pfizer | N=50 --> 10 | Trial completion date: Dec 2025 --> Feb 2024 | Trial primary completion date: Dec 2024 --> Feb 2024
    Enrollment change • Trial completion date • Trial primary completion date • Combination therapy
    |
    pegylated liposomal doxorubicin • maplirpacept (TTI-622)
    6ms
    A Study to Learn About the Effects of Two Study Medicines (Maplirpacept [PF-07901801] And Glofitamab) When Given Together In People With Relapsed Or Refractory Diffuse Large B Cell Lymphoma. (clinicaltrials.gov)
    P1b/2, N=70, Recruiting, Pfizer | Trial completion date: Jul 2027 --> Feb 2029 | Trial primary completion date: Sep 2026 --> Mar 2027
    Trial completion date • Trial primary completion date • Combination therapy
    |
    Gazyva (obinutuzumab) • Columvi (glofitamab-gxbm) • maplirpacept (TTI-622)
    6ms
    The CD47-Blocking Immune Checkpoint Inhibitor Maplirpacept Does Not Interfere with Blood Transfusion Compatibility Testing (ASH 2023)
    CD47 expression on RBCs was shown to interfere with pre-transfusion laboratory testing in patients treated with the anti-CD47 mAb, Hu5F9-G4 (Velliquette et al. Here we demonstrate that interference with blood compatibility testing is dependent upon the type of CD47-blocking agent. Decoy receptors such as Maplirpacept, unlike anti-CD47 mAb, do not interfere with blood group serologic testing, which may confer a significant clinical advantage by negating the need for additional approaches to prevent interference.
    Checkpoint inhibition • IO biomarker
    |
    CD47 (CD47 Molecule) • SIRPA (Signal Regulatory Protein Alpha)
    |
    CD47 expression
    |
    magrolimab (GS-4721) • maplirpacept (TTI-622)
    7ms
    Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma (clinicaltrials.gov)
    P1b/2, N=70, Recruiting, Pfizer | Trial completion date: Jul 2026 --> Mar 2029 | Trial primary completion date: Jan 2026 --> Mar 2027
    Trial completion date • Trial primary completion date
    |
    lenalidomide • Monjuvi (tafasitamab-cxix) • maplirpacept (TTI-622)
    7ms
    TTI-622-01: A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma (clinicaltrials.gov)
    P1a/1b, N=177, Active, not recruiting, Pfizer | Recruiting --> Active, not recruiting | N=476 --> 177 | Trial completion date: Oct 2025 --> Apr 2025 | Trial primary completion date: Oct 2024 --> Apr 2024
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation • TP53 wild-type
    |
    Venclexta (venetoclax) • Rituxan (rituximab) • azacitidine • carfilzomib • Sarclisa (isatuximab-irfc) • dexamethasone injection • maplirpacept (TTI-622)
    10ms
    TTI-622-01: A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma (clinicaltrials.gov)
    P1a/1b, N=476, Recruiting, Pfizer | Trial completion date: Jan 2026 --> Sep 2025 | Trial primary completion date: Jan 2025 --> Sep 2024
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation • TP53 wild-type
    |
    Venclexta (venetoclax) • Rituxan (rituximab) • azacitidine • carfilzomib • Sarclisa (isatuximab-irfc) • dexamethasone injection • maplirpacept (TTI-622)
    10ms
    A Study to Learn About the Study Medicine (Maplirpacept) in People With Advanced Non-Hodgkin Lymphoma or Multiple Myeloma in China (clinicaltrials.gov)
    P1, N=9, Recruiting, Pfizer | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    maplirpacept (TTI-622)
    10ms
    TTI-622-01: A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma (clinicaltrials.gov)
    P1a/1b, N=476, Recruiting, Pfizer | Trial completion date: Jul 2025 --> Jan 2026 | Trial primary completion date: Jul 2024 --> Jan 2025
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation • TP53 wild-type
    |
    Venclexta (venetoclax) • Rituxan (rituximab) • azacitidine • carfilzomib • Sarclisa (isatuximab-irfc) • dexamethasone injection • maplirpacept (TTI-622)
    11ms
    MagnetisMM-20: A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma (clinicaltrials.gov)
    P1b, N=14, Recruiting, Pfizer | N=56 --> 14
    Enrollment change • Combination therapy
    |
    carfilzomib • Elrexfio (elranatamab-bcmm) • maplirpacept (TTI-622)
    11ms
    A Study to Learn About the Study Medicine (Maplirpacept) in People With Advanced Non-Hodgkin Lymphoma or Multiple Myeloma in China (clinicaltrials.gov)
    P1, N=9, Not yet recruiting, Pfizer
    New P1 trial • Metastases
    |
    maplirpacept (TTI-622)
    12ms
    TTI-622-01: A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma (clinicaltrials.gov)
    P1a/1b, N=476, Recruiting, Pfizer | Trial completion date: Jun 2026 --> Jul 2025 | Trial primary completion date: May 2025 --> Jul 2024
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation • TP53 wild-type
    |
    Venclexta (venetoclax) • Rituxan (rituximab) • azacitidine • carfilzomib • Sarclisa (isatuximab-irfc) • dexamethasone injection • maplirpacept (TTI-622)
    12ms
    A Study of TTI-622 in Combination With Daratumumab Hyaluronidase-fihj in People With Multiple Myeloma (clinicaltrials.gov)
    P1, N=32, Recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Oct 2023 --> Oct 2025 | Trial primary completion date: Oct 2023 --> Oct 2025
    Trial completion date • Trial primary completion date • Combination therapy
    |
    Darzalex Faspro (daratumumab/hyaluronidase) • maplirpacept (TTI-622)
    12ms
    MagnetisMM-20: A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma (clinicaltrials.gov)
    P1b, N=56, Recruiting, Pfizer | N=14 --> 56 | Trial completion date: Aug 2026 --> Jul 2027 | Trial primary completion date: Nov 2024 --> Aug 2025
    Enrollment change • Trial completion date • Trial primary completion date • Combination therapy
    |
    carfilzomib • Elrexfio (elranatamab-bcmm) • maplirpacept (TTI-622)
    1year
    Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With Platinum-Resistant Ovarian Cancer (clinicaltrials.gov)
    P1/2, N=50, Recruiting, Pfizer | Phase classification: P2 --> P1/2 | Trial completion date: Sep 2025 --> Dec 2025 | Trial primary completion date: Sep 2024 --> Dec 2024
    Phase classification • Trial completion date • Trial primary completion date • Combination therapy
    |
    pegylated liposomal doxorubicin • maplirpacept (TTI-622)
    1year
    TTI-622 and TTI-621 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma (clinicaltrials.gov)
    P2, N=62, Recruiting, Mayo Clinic | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy
    |
    PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6) • IRF4 (Interferon regulatory factor 4)
    |
    ALK positive • BCL6 rearrangement • BCL2 rearrangement
    |
    Keytruda (pembrolizumab) • maplirpacept (TTI-622) • ontorpacept (PF-07901800)
    1year
    TTI-622-01: A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma (clinicaltrials.gov)
    P1a/1b, N=476, Recruiting, Pfizer | Trial completion date: Dec 2025 --> Jun 2026 | Trial primary completion date: Nov 2024 --> May 2025
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation • TP53 wild-type
    |
    Venclexta (venetoclax) • Rituxan (rituximab) • azacitidine • carfilzomib • Sarclisa (isatuximab-irfc) • dexamethasone injection • maplirpacept (TTI-622)
    over1year
    TTI-622-01: A Clinical Trial to Learn About the Study Medicine (Called TTI-622) Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma (MM) (clinicaltrials.gov)
    P1a/1b, N=368, Recruiting, Pfizer | Trial completion date: Feb 2025 --> Aug 2025 | Trial primary completion date: Jan 2024 --> Jul 2024
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation • TP53 wild-type
    |
    Venclexta (venetoclax) • Rituxan (rituximab) • azacitidine • carfilzomib • Sarclisa (isatuximab-irfc) • dexamethasone injection • maplirpacept (TTI-622)
    over1year
    Serological Interference in Pretransfusion Testing in Patients Receiving TTI-622 (SIRPα-IgG4 Fc), a CD47-Innate Immune Checkpoint Inhibitor (AABB 2022)
    Study Design/ Samples from ten patients receiving TTI-622 (combination with azacitidine (AZA), AZA + venetoclax or carfilzomib + dexamethasone) were studied. We and others have reported interference in pretransfusion testing with anti-CD47 therapeutics (Transfusion 2019;59;730) and noted that interference characteristics will vary depending on drug IgG subclass and design. For TTI-622, no interference was observed in tube testing with PEG or LISS with Immucor or Ortho anti-IgG. Gel methods were the most sensitive to interference, particularly Bio-Rad.
    Clinical • Checkpoint inhibition
    |
    CD47 (CD47 Molecule) • SIRPA (Signal Regulatory Protein Alpha)
    |
    Venclexta (venetoclax) • azacitidine • carfilzomib • maplirpacept (TTI-622)
    over1year
    TTI-622 and TTI-621 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma (clinicaltrials.gov)
    P2, N=62, Not yet recruiting, Mayo Clinic
    New P2 trial • Combination therapy
    |
    PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6) • IRF4 (Interferon regulatory factor 4)
    |
    ALK positive • BCL6 rearrangement • BCL2 rearrangement
    |
    Keytruda (pembrolizumab) • maplirpacept (TTI-622) • ontorpacept (PF-07901800)
    almost2years
    TTI-622-01: A Clinical Trial to Learn About the Study Medicine (Called TTI-622) Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma (MM) (clinicaltrials.gov)
    P1a/1b, N=368, Recruiting, Pfizer | Trial completion date: Jun 2024 --> Feb 2025 | Trial primary completion date: Jun 2023 --> Jan 2024
    Trial completion date • Trial primary completion date • Combination therapy
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation • TP53 wild-type
    |
    Venclexta (venetoclax) • Rituxan (rituximab) • azacitidine • carfilzomib • Sarclisa (isatuximab-irfc) • dexamethasone injection • maplirpacept (TTI-622)
    almost2years
    CD47-BLOCKER TTI-622 COMBINED WITH AZACITIDINE IN PATIENTS WITH TP53-MUTATED ACUTE MYELOID LEUKEMIA (AML) AND WITH AZACITIDINE + VENETOCLAX IN ELDERLY OR UNFIT PATIENTS WITH TP53-WILDTYPE AML (EHA 2022)
    Response assessment is per the ELN2017 criteria. Results Results N/A (trial-in-progress) Conclusion Conclusion N/A (trial-in-progress)
    Clinical
    |
    TP53 (Tumor protein P53) • CD47 (CD47 Molecule) • SIRPA (Signal Regulatory Protein Alpha)
    |
    TP53 mutation • TP53 wild-type
    |
    Venclexta (venetoclax) • azacitidine • maplirpacept (TTI-622)
    2years
    TTI-622-01: A Trial of TTI-622 in Patients With Advanced Hematologic Malignancies (clinicaltrials.gov)
    P1a/1b, N=350, Recruiting, Trillium Therapeutics Inc. | N=150 --> 350 | Trial completion date: Dec 2022 --> Jun 2024 | Trial primary completion date: Apr 2022 --> Jun 2023
    Enrollment change • Trial completion date • Trial primary completion date
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation • TP53 wild-type
    |
    Venclexta (venetoclax) • Rituxan (rituximab) • azacitidine • carfilzomib • maplirpacept (TTI-622)
    over2years
    CD47-Blocker TTI-622 Shows Single-Agent Activity in Patients with Advanced Relapsed or Refractory Lymphoma: Update from the Ongoing First-in-Human Dose Escalation Study (ASH 2021)
    Updated data including additional patients will be presented at the conference. Based on these results demonstrating promising single-agent activity as well as good tolerability, TTI-622 is currently being investigated in combination regimens in a range of hematologic malignancies.
    Clinical • P1 data • IO biomarker
    |
    CD47 (CD47 Molecule) • SIRPA (Signal Regulatory Protein Alpha)
    |
    CD47 overexpression
    |
    maplirpacept (TTI-622)
    over3years
    [VIRTUAL] Investigational CD47-Blocker TTI-622 Shows Single-Agent Activity in Patients with Advanced Relapsed or Refractory Lymphoma: Update from the Ongoing First-in-Human Dose Escalation Study (ASH 2020)
    TTI-622 has shown activity in R/R lymphoma with objective responses across a broad dose range (0.8–8 mg/kg) and in multiple histologies. The study is currently evaluating the 8 mg/kg dose level.
    Clinical • P1 data • IO biomarker
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    maplirpacept (TTI-622)